Anticoagulation Forum/LinkedIn
Jun 22, 2026, 15:08
Apixaban vs. Rivaroxaban in Acute VTE – Uncoiling COBRRA and Its Clinical Implications – Anticoagulation Forum
Anticoagulation Forum shared a post on LinkedIn:
“Recording now available!
We are grateful to our expert faculty for sharing their time, and their thoughtful discussions, and insights during our recent webinar:
Apixaban vs. Rivaroxaban in Acute VTE: Uncoiling COBRRA and Its Clinical Implications
This session explored the clinical questions behind the COBRRA trial, including retrospective evidence, potential pharmacologic explanations, study design, key findings, and practical implications for frontline VTE care.
Faculty:
- Arthur Allen, PharmD
- Lana Castellucci, MD
- Steven Deitelzweig, MD
- Jori May, MD
If you missed the live webinar, want to revisit the discussion, or know a colleague who may benefit, the recording is available to watch for free on our Archived Webinars page.
-
Nov 9, 2026, 13:48PF4-ELISA–Negative HIT: Are We Missing a New Class of Anti-PF4 Immunothrombotic Disease?
-
Nov 9, 2026, 13:07Nandini Sadasivam: Gene Therapy for Sickle Cell Disease and Thalassaemia
-
Nov 9, 2026, 13:04Raising Awareness of Bleeding Disorders in Women and Girls – EHC
-
Nov 9, 2026, 12:59Rahul Bohra: Exploring the Complex Mechanisms of Sickle Cell Disease
-
Nov 9, 2026, 12:53Three Years of Movement and Thrombosis Awareness in the Czech Republic – World Thrombosis day
-
Nov 9, 2026, 12:51Octavio Marques Pontes-Neto: Intensive Blood-Pressure Control Reduces Cardiovascular Events After Ischemic Stroke
-
Nov 9, 2026, 12:49Irma Bagdoniene: What Really Makes Us Live Longer
-
Nov 9, 2026, 12:47Imo Akpan: Announcing the 2027 Women’s Hematology Summit
-
Nov 9, 2026, 12:45Shadi Yaghi: Rethinking Antithrombotic Therapy After Stroke